

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,700,276 B2  
APPLICATION NO. : 10/563503  
DATED : April 20, 2010  
INVENTOR(S) : Stordeur et al.


Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 4, Line 35, "nucleic add stabilising" should be changed to --nucleic acid stabilising--  
Column 4, Line 42, "of step (f using" should be changed to --of step (f) using--  
Column 6, Line 28, "are selected from one" should be changed to --selected from one--  
Column 6, Line 29, "tetanous toxoid," should be changed to --tetanus toxoid,--  
Column 7, Line 13, "the RNAlater reagent" should be changed to --the RNA later reagent--  
Column 7, Line 17, "NaCl alone or an" should be changed to --NaCl alone or an--  
Column 8, Line 61, "1.42-43). Therefore," should be changed to --1.42-43). Therefore,--  
Column 11, Line 14, "is tetanous toxoid." should be changed to --is tetanus toxoid.--  
Column 18, Line 59, "directly of indirectly" should be changed to --directly or indirectly--  
Column 19, Line 2, "with an identical similar" should be changed to --with an  
identical/similar--  
Column 19, Line 53, "the pulsed/nonpulsed cells," should be changed to  
--the pulsed/non-pulsed cells,--  
Column 26, Line 8, "the same individual," should be changed to --the same individuals,--  
Column 26, Line 32, "tetradecyltrimethylammonium oxalate" should be changed to  
--tetradecyltrimethylammonium oxalate--  
Column 29, Line 21, "(dendritc cells," should be changed to --(dendritic cells,--  
Column 29, Line 64, "epitope-specifiq CTLs" should be changed to --epitope-specific CTLs--  
Column 30, Line 44, "is damaged Would" should be changed to --is damaged would--  
Column 30, Line 48, "subclinical episodes of" should be changed to --sub-clinical episodes of--  
Column 31, Line 15, "Pure<sup>TM</sup>0 instrument" should be changed to -- Pure<sup>TM</sup> instrument--

Signed and Sealed this

Seventh Day of September, 2010



David J. Kappos  
*Director of the United States Patent and Trademark Office*

Column 31, Line 45, “of the PAXgene™**0** tube’s” should be changed to --of the PAXgene™ tube’s--

Column 33, Line 25, “and IFN $\gamma$  mRNAs” should be changed to --and IFN- $\gamma$  mRNAs--

Column 35, Line 9, “quantfication errors,” should be changed to --quantification errors,--

Column 35, Line 64, “in vitro incubaton” should be changed to --in vitro incubation--

Column 36, Line 25, “to monitor alloreactive” should be changed to --to monitor alloreactive--

Column 37, Line 14, “6FaM-” should be changed to --6Fam- --

Column 38, Lines 15-16, “dilution of PCR” should be changed to --dilutions of PCR--